The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Varicella Attenuated Live Vaccine-Global Market Insights and Sales Trends 2025
Synopsis
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
The global Varicella Attenuated Live Vaccine market size is expected to reach US$ 3440.8 million by 2029, growing at a CAGR of 4.3% from 2023 to 2029. The market is mainly driven by the significant applications of Varicella Attenuated Live Vaccine in various end use industries. The expanding demands from the Kids Injection and Adults Injection, are propelling Varicella Attenuated Live Vaccine market. Monovalent Vaccine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Combination Vaccine segment is estimated at % CAGR for the next seven-year period.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Varicella Attenuated Live Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Varicella Attenuated Live Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Varicella Attenuated Live Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Varicella Attenuated Live Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Varicella Attenuated Live Vaccine covered in this report include Merck, BCHT, Shanghai Institute, GSK, Keygen, Green Cross, Biken, Shanghai Rongsheng Biotech and Changchun Changsheng Life Sciences Limited, etc.
The global Varicella Attenuated Live Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
Global Varicella Attenuated Live Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Varicella Attenuated Live Vaccine market, Segment by Type:
Monovalent Vaccine
Combination Vaccine
Global Varicella Attenuated Live Vaccine market, by Application
Kids Injection
Adults Injection
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Varicella Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
The global Varicella Attenuated Live Vaccine market size is expected to reach US$ 3440.8 million by 2029, growing at a CAGR of 4.3% from 2023 to 2029. The market is mainly driven by the significant applications of Varicella Attenuated Live Vaccine in various end use industries. The expanding demands from the Kids Injection and Adults Injection, are propelling Varicella Attenuated Live Vaccine market. Monovalent Vaccine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Combination Vaccine segment is estimated at % CAGR for the next seven-year period.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Varicella Attenuated Live Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Varicella Attenuated Live Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Varicella Attenuated Live Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Varicella Attenuated Live Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Varicella Attenuated Live Vaccine covered in this report include Merck, BCHT, Shanghai Institute, GSK, Keygen, Green Cross, Biken, Shanghai Rongsheng Biotech and Changchun Changsheng Life Sciences Limited, etc.
The global Varicella Attenuated Live Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
Global Varicella Attenuated Live Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Varicella Attenuated Live Vaccine market, Segment by Type:
Monovalent Vaccine
Combination Vaccine
Global Varicella Attenuated Live Vaccine market, by Application
Kids Injection
Adults Injection
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Varicella Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Varicella Attenuated Live Vaccine Market Overview
1.1 Varicella Attenuated Live Vaccine Product Overview
1.2 Varicella Attenuated Live Vaccine Market Segment by Type
1.2.1 Monovalent Vaccine
1.2.2 Combination Vaccine
1.3 Global Varicella Attenuated Live Vaccine Market Size by Type
1.3.1 Global Varicella Attenuated Live Vaccine Market Size Overview by Type (2018-2029)
1.3.2 Global Varicella Attenuated Live Vaccine Historic Market Size Review by Type (2018-2023)
1.3.3 Global Varicella Attenuated Live Vaccine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Varicella Attenuated Live Vaccine Sales Breakdown by Type (2018-2023)
1.4.2 Europe Varicella Attenuated Live Vaccine Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Varicella Attenuated Live Vaccine Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Varicella Attenuated Live Vaccine Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Varicella Attenuated Live Vaccine Sales Breakdown by Type (2018-2023)
2 Global Varicella Attenuated Live Vaccine Market Competition by Company
2.1 Global Top Players by Varicella Attenuated Live Vaccine Sales (2018-2023)
2.2 Global Top Players by Varicella Attenuated Live Vaccine Revenue (2018-2023)
2.3 Global Top Players by Varicella Attenuated Live Vaccine Price (2018-2023)
2.4 Global Top Manufacturers Varicella Attenuated Live Vaccine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Varicella Attenuated Live Vaccine Market Competitive Situation and Trends
2.5.1 Varicella Attenuated Live Vaccine Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Varicella Attenuated Live Vaccine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccine as of 2022)
2.7 Date of Key Manufacturers Enter into Varicella Attenuated Live Vaccine Market
2.8 Key Manufacturers Varicella Attenuated Live Vaccine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Varicella Attenuated Live Vaccine Status and Outlook by Region
3.1 Global Varicella Attenuated Live Vaccine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Varicella Attenuated Live Vaccine Historic Market Size by Region
3.2.1 Global Varicella Attenuated Live Vaccine Sales in Volume by Region (2018-2023)
3.2.2 Global Varicella Attenuated Live Vaccine Sales in Value by Region (2018-2023)
3.2.3 Global Varicella Attenuated Live Vaccine Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Varicella Attenuated Live Vaccine Forecasted Market Size by Region
3.3.1 Global Varicella Attenuated Live Vaccine Sales in Volume by Region (2024-2029)
3.3.2 Global Varicella Attenuated Live Vaccine Sales in Value by Region (2024-2029)
3.3.3 Global Varicella Attenuated Live Vaccine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Varicella Attenuated Live Vaccine by Application
4.1 Varicella Attenuated Live Vaccine Market Segment by Application
4.1.1 Kids Injection
4.1.2 Adults Injection
4.2 Global Varicella Attenuated Live Vaccine Market Size by Application
4.2.1 Global Varicella Attenuated Live Vaccine Market Size Overview by Application (2018-2029)
4.2.2 Global Varicella Attenuated Live Vaccine Historic Market Size Review by Application (2018-2023)
4.2.3 Global Varicella Attenuated Live Vaccine Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Varicella Attenuated Live Vaccine Sales Breakdown by Application (2018-2023)
4.3.2 Europe Varicella Attenuated Live Vaccine Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Varicella Attenuated Live Vaccine Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Varicella Attenuated Live Vaccine Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Varicella Attenuated Live Vaccine Sales Breakdown by Application (2018-2023)
5 North America Varicella Attenuated Live Vaccine by Country
5.1 North America Varicella Attenuated Live Vaccine Historic Market Size by Country
5.1.1 North America Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Varicella Attenuated Live Vaccine Sales in Volume by Country (2018-2023)
5.1.3 North America Varicella Attenuated Live Vaccine Sales in Value by Country (2018-2023)
5.2 North America Varicella Attenuated Live Vaccine Forecasted Market Size by Country
5.2.1 North America Varicella Attenuated Live Vaccine Sales in Volume by Country (2024-2029)
5.2.2 North America Varicella Attenuated Live Vaccine Sales in Value by Country (2024-2029)
6 Europe Varicella Attenuated Live Vaccine by Country
6.1 Europe Varicella Attenuated Live Vaccine Historic Market Size by Country
6.1.1 Europe Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Varicella Attenuated Live Vaccine Sales in Volume by Country (2018-2023)
6.1.3 Europe Varicella Attenuated Live Vaccine Sales in Value by Country (2018-2023)
6.2 Europe Varicella Attenuated Live Vaccine Forecasted Market Size by Country
6.2.1 Europe Varicella Attenuated Live Vaccine Sales in Volume by Country (2024-2029)
6.2.2 Europe Varicella Attenuated Live Vaccine Sales in Value by Country (2024-2029)
7 Asia-Pacific Varicella Attenuated Live Vaccine by Region
7.1 Asia-Pacific Varicella Attenuated Live Vaccine Historic Market Size by Region
7.1.1 Asia-Pacific Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Varicella Attenuated Live Vaccine Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Varicella Attenuated Live Vaccine Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Varicella Attenuated Live Vaccine Forecasted Market Size by Region
7.2.1 Asia-Pacific Varicella Attenuated Live Vaccine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Varicella Attenuated Live Vaccine Sales in Value by Region (2024-2029)
8 Latin America Varicella Attenuated Live Vaccine by Country
8.1 Latin America Varicella Attenuated Live Vaccine Historic Market Size by Country
8.1.1 Latin America Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Varicella Attenuated Live Vaccine Sales in Volume by Country (2018-2023)
8.1.3 Latin America Varicella Attenuated Live Vaccine Sales in Value by Country (2018-2023)
8.2 Latin America Varicella Attenuated Live Vaccine Forecasted Market Size by Country
8.2.1 Latin America Varicella Attenuated Live Vaccine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Varicella Attenuated Live Vaccine Sales in Value by Country (2024-2029)
9 Middle East and Africa Varicella Attenuated Live Vaccine by Country
9.1 Middle East and Africa Varicella Attenuated Live Vaccine Historic Market Size by Country
9.1.1 Middle East and Africa Varicella Attenuated Live Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Varicella Attenuated Live Vaccine Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Varicella Attenuated Live Vaccine Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Varicella Attenuated Live Vaccine Forecasted Market Size by Country
9.2.1 Middle East and Africa Varicella Attenuated Live Vaccine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Varicella Attenuated Live Vaccine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Merck
10.1.1 Merck Company Information
10.1.2 Merck Introduction and Business Overview
10.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Merck Varicella Attenuated Live Vaccine Products Offered
10.1.5 Merck Recent Development
10.2 BCHT
10.2.1 BCHT Company Information
10.2.2 BCHT Introduction and Business Overview
10.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 BCHT Varicella Attenuated Live Vaccine Products Offered
10.2.5 BCHT Recent Development
10.3 Shanghai Institute
10.3.1 Shanghai Institute Company Information
10.3.2 Shanghai Institute Introduction and Business Overview
10.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Products Offered
10.3.5 Shanghai Institute Recent Development
10.4 GSK
10.4.1 GSK Company Information
10.4.2 GSK Introduction and Business Overview
10.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 GSK Varicella Attenuated Live Vaccine Products Offered
10.4.5 GSK Recent Development
10.5 Keygen
10.5.1 Keygen Company Information
10.5.2 Keygen Introduction and Business Overview
10.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Keygen Varicella Attenuated Live Vaccine Products Offered
10.5.5 Keygen Recent Development
10.6 Green Cross
10.6.1 Green Cross Company Information
10.6.2 Green Cross Introduction and Business Overview
10.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Green Cross Varicella Attenuated Live Vaccine Products Offered
10.6.5 Green Cross Recent Development
10.7 Biken
10.7.1 Biken Company Information
10.7.2 Biken Introduction and Business Overview
10.7.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Biken Varicella Attenuated Live Vaccine Products Offered
10.7.5 Biken Recent Development
10.8 Shanghai Rongsheng Biotech
10.8.1 Shanghai Rongsheng Biotech Company Information
10.8.2 Shanghai Rongsheng Biotech Introduction and Business Overview
10.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Products Offered
10.8.5 Shanghai Rongsheng Biotech Recent Development
10.9 Changchun Changsheng Life Sciences Limited
10.9.1 Changchun Changsheng Life Sciences Limited Company Information
10.9.2 Changchun Changsheng Life Sciences Limited Introduction and Business Overview
10.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Products Offered
10.9.5 Changchun Changsheng Life Sciences Limited Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Varicella Attenuated Live Vaccine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Varicella Attenuated Live Vaccine Industrial Chain Analysis
11.4 Varicella Attenuated Live Vaccine Market Dynamics
11.4.1 Varicella Attenuated Live Vaccine Industry Trends
11.4.2 Varicella Attenuated Live Vaccine Market Drivers
11.4.3 Varicella Attenuated Live Vaccine Market Challenges
11.4.4 Varicella Attenuated Live Vaccine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Varicella Attenuated Live Vaccine Distributors
12.3 Varicella Attenuated Live Vaccine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
